In men who presented with presumed localized disease (Groups 1 and 2), 18% (6/34) were considered to have undergone guideline-directed PSA screening, compared to 15% (19/123) in patients who presented with metastatic disease (Groups 3 and 4). The gene discussed is KLK3; the disease is metastatic neoplasm.